Please use this identifier to cite or link to this item:
|Title:||Preclinical evaluation of anti-HER2 2Rs15d nanobody labeled with 225Ac|
|Authors:||PRUSZYNSKI MAREK; D’HUYVETTER MATTHIAS; CĘDROWSKA E; LAHOUTTE TONY; BRUCHERTSEIFER FRANK; MORGENSTERN ALFRED|
|Publisher:||European Commission - Joint Research Centre|
|Type:||Articles in periodicals and books|
|Abstract:||Human Epidermal Growth Factor Receptor type 2 (HER2) is overexpressed in a series of human cancer types such as breast, ovarian, colorectal and urothelial carcinomas and is often associated with a higher recurrence rate and a shorter time to relapse. Intact mAbs are not always ideal vectors for radioimmunotherapy due to their slow pharmacokinetic and normal-tissue clearance. Nanobodies (nbs) are small antibody fragments (~15kDa) with beneficial pharmacokinetic properties, and those targeted to HER2 are very attractive vectors for targeted radionuclide therapy (TRT). The aim of this study was to develop and evaluate a potential molecular-targeted drug based on the anti-HER2-Nb labeled with 225Ac|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.